# Anhui Huibang Bioengineering Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anhui-huibang-bioengineering-co

- Industry: Biotechnology
- Headquarters: Hefei, China
- Website: www.hbswgc.com
- Latest round: Series C (Dec 23, 2021)
- Investors on record: 4

## About

Established in 2013 and based in Hefei, China, Anhui Huibang Bioengineering Co., Ltd. is a biotech company that focuses on the development of in vitro diagnostic reagents. In 2016, the company launched a urine iodine quantitative analysis system. In 2017, the company established a subsidiary Hefei Huibang Biotechnology. In 2019, the company was successfully listed in the Anhui Equity Custody and Trading Center with the listing code: 630215.

The company engages in the development of in vitro diagnostic reagents. Its main products include tumor diagnostic reagents, maternal and child health diagnostic reagents, cardiovascular disease detection reagents, and POCT diagnostic reagents. The non-invasive detection system for diabetic kidney disease provides renal biopsy, urine microalbumin and urine haptoglobin and other services.

## Funding rounds

- Series C, Dec 23, 2021 — Yunsong Capital
- Series B, Jan 18, 2021 — SAIF Partners, Keyin Fund
- Series A, Aug 23, 2018 — Milestone Asset Management

## Investors

- Milestone Asset Management — Series A
- SAIF Partners (https://capitalatlas.ai/funds/saif-partners) — Series B
- Keyin Fund (https://capitalatlas.ai/funds/keyin-fund) — Series B
- Yunsong Capital (https://capitalatlas.ai/funds/yunsong-capital) — Series C